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comparing the safety and efficacy of carotid artery
stenting versus endarterectomy in symptomatic
patients, the quality of data continues to improve. A
recent Cochrane collaboration review6 concluded that
‘data from randomised trials comparing endovascular
treatment for carotid artery stenosis with carotid
endarterectomy suggest that the two treatments have
similar early risks of death or stroke and similar long-
term benefits’. The review commented that because of
the heterogeneity of data, wide confidence intervals
and also presumably because of a lack of long-term
follow up, recruitment to on-going trials for sympto-
matic patients should be encouraged.
However, a simple review of the published
literature on the subject of carotid artery stenting
shows that nearly half the patients treated with this
new technology are asymptomatic. In the global
carotid registry7 asymptomatic patients accounted
for 47% of those reported, but in some centres patients
with asymptomatic carotid disease accounted for 74%
of treatments. Similarly in the SAPPHIRE Trial,5 70.1%
of patients in the randomised group were asympto-
matic. What then is the quality of the date to support
this treatment, how does it compare against carotid
endarterectomy and best medical therapy, and is it cost
efficient?
There is only one randomised trial comparing
carotid stents versus carotid endarterectomy in
asymptomatic carotid disease that has been pub-
lished.8 The quality of the data that appeared on the
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concluded that the treatments were equally efficacious
and of similar costs. Away from this trial the quality of
data is also poor. Often results of using carotid artery
stents in asymptomatic patients are not separated from
symptomatic patients and the numbers are mainly
small. The global registry7 is self-reported and details
a 30-day complication rate of 2.5% in patients were
cerebral protection was used and 4.78% in patients
where there is no cerebral protection. The 30-day
complication rate in the published literature where the
results are separated out, details a peri-procedural
adverse event rate of between 0 and 11.1%.9–32 Within
the SAPPHIRE Trial,5 the 30-day risk of stroke and
death was 5.4% and at 1 year the risks were 9.9%.
These patients were considered to be surgically high
risk and it is, therefore, not surprising to find that the
comparative surgical figures for these two periods in
this study are 10.2 and 21.5%. Apart from the short
follow-up in the SAPPHIRE Trial, there are no long-
term data to indicate that carotid artery stenting
provides any improved prophylaxis against stroke
over and above either best medical therapy or carotid
endarterectomy.
How cost efficient is carotid artery stenting? With-
out any good published literature on the subject with
long-term outcomes this is an impossible question to
answer. The available literature on the comparative
costs of stenting and surgery are contradictory and
necessarily reflect the health system within which they
were compared. However, if it is assumed that the
outcome results are as good as carotid endarterectomy
in a group of patients who do not receive what is
currently considered to be best medical therapy, then it
can be questioned if it is in the best interests of any
health system to offer a form of therapy that willEur J Vasc Endovasc Surg 30, 461–463 (2005)
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The implication of course is that 947 patients will have
had a procedure that conferred no benefit and
presumes a peri-procedural event rate of 3%. If the
event rate is higher than this then the conferred benefit
upon the population is of even less benefit. The
published literature would indicate that some units
do run a 30-day complication rate higher than 3% and
within the SAPPHIRE study a procedural risk of 5.4%
means that only 32 strokes will have been prevented
after 1000 treatments at 5 years (always assuming the
high-risk patients live that long), with 968 patients
undergoing treatment that will have conferred no
benefit.
It is generally considered, particularly by stroke
physicians, that best medical therapy has progressed
considerably since, the major carotid endarterectomy
trials. Whether this renders carotid endarterectomy
obsolete cannot currently be answered since, in both
the ACST and ACAS Trials that best medical therapy
was not mandated or prescribed. The role of best
medical therapies compared to surgery recently
received an editorial in this journal.33 It was recog-
nised that the introduction of current concepts in anti-
platelet therapy, statins, ACE inhibitors and appro-
priate blood pressure control may confer some
advantages over the historical understanding of the
natural history of asymptomatic disease. However, to
suggest that surgical intervention remains of value
simply because clinicians and surgeons are poor at
prescribing modern concepts of best medical therapy33
is a poor argument. Perhaps more time and effort
should be dedicated to the introduction and mainten-
ance of optimal therapy rather than pursuing an
asymptomatic stenosis on which to operate. In
addition, the concept that, because there is a lag
phase in the benefit conferred by best medical therapy
in patients with carotid disease, then carotid endarter-
ectomy is advantageous,33 surely does not stand up to
close scrutiny. There is also a lag phase in the benefit of
carotid endarterectomy since, any long-term benefit
from active intervention is delayed because the initial
peri-surgical complication rate. The simple answer,
therefore, is that we have no data at present to suggest
carotid artery stenting is of benefit over and above best
medical therapy in patients with asymptomatic
carotid disease. Perhaps, since, surgical trials did not
deliver what is now considered to be best medical
therapy, the same can also be said of carotid
endarterectomy in asymptomatic disease.
How then should we proceed? Surely this discus-
sion opens the way for a trial of both carotid artery
stenting and carotid endarterectomy versus best
medical therapy. The transatlantic carotid interventionEur J Vasc Endovasc Surg Vol 30, 11 2005trial (TACIT) is a multinational multidisciplinary
collaboration involving surgeons, radiologists, cardi-
ologists and stroke physicians across Europe and the
USA. It aims to have secured funding and begin the
randomisation of 2400 patients between prescribed
best medical therapy and endarterectomy or stenting
by 2006. The trialists are looking for 100 centres across
the Atlantic and it is hoped that units will see fit to
participate in what is considered to be an important
study. For further details please feel free to contact me
at p.a.gaines@sheffield.ac.uk and I will pass your
details on to the appropriate country co-ordinator.References
1 Alberts MJ. Results of a multicenter prospective randomized
trial of carotid artery stenting versus carotid endarterectomy.
Stroke 2001;32:325 [abstract].
2 CAVATAS Investigators. Endovascular versus surgical treatment
in patients with carotid stenosis in the carotid and vertebral
artery transluminal angioplasty study (CAVATAS): A random-
ised trial. Lancet 2001;357:1729–1737.
3 Brooks W, McClure R, Jones M, Coleman T, Breathitt L.
Carotid angioplasty and stenting versus carotid endarterectomy:
Randomized trial in a community hospital. J Am Coll Cardiol 2001;
38:1589–1595.
4 Naylor AR, Bolia A, Abbott RJ, Pye IF, Smith J, Lennard N
et al. Randomized study of carotid angioplasty and stenting
versus carotid endarterectomy: A stopped trial. J Vasc Surg 1998;
28(2):326–334.
5 Yadav JS, Wholey MH, Kuntz RE, Fayad P, Katzen BT,
Mishkel GJ et al. Protected carotid-artery stenting versus
endarterectomy in high-risk patients. N Engl J Med 2004;
351(15):1493–1501.
6 Coward L, Featherstone R, Brown M. Percutaneous translum-
inal angioplasty and stenting for carotid artery stenosis (cochrane
review). Willey, The Cochrane Library. Cichester (UK), 2004.
7 Wholey MH, Al-Mubarak N. Update review of the global
carotid stent registry. Catheter Cardiovasc Interv 2003;60:259–266.
8 Brooks W, McClure R, Jones M, Coleman T, Breathitt L.
Carotid angioplasty and stenting versus carotid endarterectomy
for treatment of asymptomatic carotid stenosis: A randomized
trial in a community hospital. Neurosurg Online 2004;54(2):318–
325.
9 Yadav JS, Roubin GS, Iyer S, Vitek J, King P, Jordan WD et al.
Elective stenting of the extracranial carotid arteries. Circulation
1997;95(2):376–381.
10 Waigand J, Gross CM, Uhlich F, Kramer J, Tamaschke C,
Vogel P et al. Elective stenting of carotid artery stenosis in
patients with severe coronary artery disease. Eur Heart J 1998;
19(9):1365–1370.
11 Lanzino GM, Mericle RA, Lopes DK, Wahkloo AK,
Guterman LR, Hopkins LN. Percutaneous transluminal angio-
plasty and stent placement for recurrent carotid artery stenosis.
J Neurosurg 1999;90:688–694.
12 Mericle RK, Kim SH, Lanzino G, Lopes DK, Wakhloo AK,
Guterman LR et al. Carotid artery angioplasty and use of stents
in high-risk patients with contralateral occlusions. J Neurosurg
1999;90:1031–1036.
13 Henry M, Amor M, Klonaris C, Henry I, Masson I, Chati Z
et al. Angioplasty and stenting of the extracranial carotid arteries.
Tex Heart Inst J 2000;27(2):150–158.
14 Ahmadi R, Willfort A, Lang W, Schillinger M, Alt E,
Gschwandtner M et al. Carotid artery stenting: Effect of learning
Carotid Artery Stenting for Patients with Asymptomatic Carotid Disease 463curve and intermediate-term morphological outcome. J Endovasc
Ther 2001;8:539–546.
15 Kirsch EC, Khangure MS, van Schie GP, Lawrence-
Brown MM, Stewart-Wynne EG, McAuliffe W. Carotid
arterial stent placement: Results and follow-up in 53 patients.
Radiology 2001;220(3):737–744.
16 Roubin GS, New G, Iyer SS, Vitek JJ, Al-Mubarak N, Liu M
et al. Immediate and late clinical outcomes of carotid artery
stenting in patients with symptomatic and asymptomatic carotid
artery stenosis. A 5-year propective analysis. Circulation 2001;103:
532–537.
17 Dietz A, Berkefeld J, Theron JG, Schmitz-Rixen T,
Zanella FE, Turowski B et al. Endovascular treatment of
symptomatic carotid stenosis using stent placement: Long-term
follow-up of patients with a balanced surgical risk/benefit ratio.
Stroke 2001;32(8):1855–1859.
18 Jaeger H, Mathias K, Drescher R, Hauth E, Bockisch G,
Demirel E et al. Clinical results of cerebral protection with a filter
device during stent implantation of the carotid artery. Cardiovasc
Intervent Radiol 2001;24(4):249–256.
19 Criado FJ, Lingelbach JM, Ledesma DF, Lucas PR. Carotid
artery stenting in a vascular surgery practice. J Vasc Surg 2002;
35(3):430–434.
20 Kao HL, Lin LY, Lu CJ, Jeng JS, Yip PK, Lee YT. Long-term results
of elective stenting for severe carotid artery stenosis in Taiwan.
Cardiology 2002;97(2):89–93.
21 Madyoon H, Braunstein E, Callcott F, Oshtory M,
Gurnsey L, Croushore L et al. Unprotected carotid artery
stenting compared to carotid endarterectomy in a community
setting. J Endovasc Ther 2002;9(6):803–809.
22 Adami CA, Scuro A, Spinamano L, Galvagni E,
Antoniucci D, Farello GA et al. Use of the parodi anti-
embolism system in carotid stenting: Italian trial results.
J Endovasc Ther 2002;9(2):147–154.
23 Whitlow PLM. Carotid artery stenting protected with an emboli
containment system. Stroke 2002;33(5):1308–1314 [Article].
24 Cremonesi A, Manetti R, Setacci F, Setacci C, Castriota F.
Protected carotid stenting: Clinical advantages and compli-
cations of embolic protection devices in 442 consecutive patients.
Stroke 2003;34(8):1936–1941.25 Bush RL, Lin PH, Bianco CC, Lawhorn TI, Hurt JE,
Lumsden AB. Carotid artery stenting in a community setting:
Experience outside of a clinical trial. Ann Vasc Surg 2003;17(6):
629–634.
26 Kastrup A, Groschel K, Krapf H, Brehm BR, Dichgans J,
Schulz JB. Early outcome of carotid angioplasty and stenting
with and without cerebral protection devices. A systematic
review of the literature. Stroke 2003;34:813–819.
27 Maleux G, Bernaerts P, Thijs V, Vaninbroukx J, Daenens K,
Fourneau I et al. Extracranial carotid artery stenting in surgically
high-risk patients using the carotid wallstent endoprosthesis:
Midterm clinical and ultrasound follow-up results. Cardiovasc
Intervent Radiol 2003;26(4):340–346.
28 Terada T, Tsuura M, Matsumoto H, Masuo O, Yamaga H,
Tsumoto T et al. Results of endovascular treatment of internal
carotid artery stenoses with a newly developed balloon
protection catheter. Neurosurgery 2003;53(3):617–623.
29 Eskandari MK, Longo GM, Vijungco JD, Morasch MD,
Pearce WH. Does carotid stenting measure up to endarter-
ectomy? A vascular surgeon’s experience. Arch Surg 2004;139(7):
734–738.
30 Debette S, Henon H, Gauvrit JY, Haulon S, Mackowiak-
Cordoliani MA, Gautier C et al. Angioplasty and stenting for
high-grade internal carotid artery stenosis: Safety study in 39
selected patients. Cerebrovasc Dis 2004;17(2–3):160–165.
31 Theiss W, Hermanek P, Mathias K, Ahmadi R, Heuser L,
Hoffmann FJ et al. Pro-CAS: A prospective registry of carotid
angioplasty and stenting. Stroke 2004;35(9):2134–2139.
32 Yen MH, Lee DS, Kapadia S, Sachar R, Bhatt DL, Bajzer CT
et al. Symptomatic patients have similar outcomes compared
with asymptomatic patients after carotid artery stenting with
emboli protection. Am J Cardiol 2005;95(2):297–300.
33 Naylor AR. Does the modern concept of ‘best medical therapy’
render carotid surgery obsolete? Eur J Vasc Endovasc Surg 2004;
28(5):457–461.
Accepted 15 July 2005
Available online 26 August 2005Eur J Vasc Endovasc Surg Vol 30, 11 2005
